Mersana Therapeutics (MRSN) Misses Q3 EPS by 18c

Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.18 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.69 million versus the consensus estimate of $7.53 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Snowflake (SNOW) call put ratio 1.6 calls to 1 put into quarter results
• St. Kitts and Nevis Integrates Biometric Enrolment With the Passport Process
• Active options: NVDA TSLA META AAPL MU DELL AMZN SPCX INTC